Consistent with our earlier findings, GHR inhibition has previously been shown to sensitize melanoma cells to paclitaxel, cisplatin [11,37,55], and the pyrimidine analog fluorouracil (5-FU) [55]. This evidence concerns the gene GHR and melanoma.